Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vaccines | 42 | 2023 | 389 | 8.340 |
Why?
|
Chagas Disease | 45 | 2024 | 277 | 6.770 |
Why?
|
Trypanosoma cruzi | 35 | 2024 | 221 | 4.770 |
Why?
|
Antigens, Helminth | 35 | 2021 | 178 | 4.590 |
Why?
|
Hookworm Infections | 31 | 2022 | 118 | 4.350 |
Why?
|
Viral Vaccines | 14 | 2020 | 304 | 4.180 |
Why?
|
Protozoan Vaccines | 20 | 2024 | 91 | 3.810 |
Why?
|
Neglected Diseases | 16 | 2023 | 147 | 3.460 |
Why?
|
Spike Glycoprotein, Coronavirus | 12 | 2023 | 222 | 3.170 |
Why?
|
Coronavirus Infections | 13 | 2020 | 651 | 2.870 |
Why?
|
Recombinant Proteins | 34 | 2023 | 2927 | 2.740 |
Why?
|
Necator americanus | 15 | 2020 | 82 | 2.630 |
Why?
|
Pneumonia, Viral | 10 | 2020 | 715 | 2.590 |
Why?
|
Vaccines, Synthetic | 28 | 2022 | 355 | 2.510 |
Why?
|
Pandemics | 16 | 2022 | 1559 | 2.390 |
Why?
|
Betacoronavirus | 10 | 2020 | 527 | 2.200 |
Why?
|
Ancylostomatoidea | 13 | 2023 | 57 | 2.170 |
Why?
|
Helminth Proteins | 12 | 2020 | 107 | 2.140 |
Why?
|
Parasitic Diseases | 5 | 2020 | 65 | 1.810 |
Why?
|
Leishmaniasis Vaccines | 5 | 2020 | 17 | 1.740 |
Why?
|
Adjuvants, Immunologic | 28 | 2023 | 657 | 1.670 |
Why?
|
Vaccination | 28 | 2022 | 1123 | 1.490 |
Why?
|
Trypanocidal Agents | 5 | 2023 | 26 | 1.480 |
Why?
|
Ascariasis | 10 | 2024 | 65 | 1.460 |
Why?
|
Nitroimidazoles | 7 | 2023 | 100 | 1.460 |
Why?
|
Saccharomycetales | 5 | 2021 | 44 | 1.410 |
Why?
|
Tropical Medicine | 7 | 2023 | 105 | 1.370 |
Why?
|
Antigens, Protozoan | 8 | 2024 | 66 | 1.320 |
Why?
|
Leishmaniasis | 5 | 2023 | 24 | 1.280 |
Why?
|
Animals | 127 | 2024 | 59536 | 1.280 |
Why?
|
Schistosomiasis | 6 | 2023 | 63 | 1.270 |
Why?
|
Communicable Disease Control | 7 | 2020 | 175 | 1.240 |
Why?
|
Schistosomiasis mansoni | 5 | 2023 | 30 | 1.190 |
Why?
|
Antibodies, Helminth | 20 | 2021 | 105 | 1.180 |
Why?
|
Biomedical Research | 8 | 2020 | 806 | 1.170 |
Why?
|
Saccharomyces cerevisiae | 5 | 2023 | 621 | 1.150 |
Why?
|
Chagas Cardiomyopathy | 8 | 2021 | 45 | 1.100 |
Why?
|
Severe Acute Respiratory Syndrome | 5 | 2020 | 82 | 1.090 |
Why?
|
Helminthiasis | 6 | 2020 | 67 | 1.060 |
Why?
|
Tetraspanins | 3 | 2016 | 42 | 1.060 |
Why?
|
Ascaris suum | 6 | 2024 | 26 | 1.040 |
Why?
|
Glutathione Transferase | 6 | 2017 | 359 | 1.030 |
Why?
|
Gene Expression | 13 | 2021 | 3570 | 1.020 |
Why?
|
Protozoan Proteins | 4 | 2018 | 114 | 1.010 |
Why?
|
Pichia | 14 | 2017 | 60 | 1.000 |
Why?
|
Phlebotomus | 2 | 2020 | 15 | 0.920 |
Why?
|
Antibodies, Neutralizing | 11 | 2023 | 541 | 0.900 |
Why?
|
Mice, Inbred BALB C | 26 | 2022 | 2314 | 0.860 |
Why?
|
Aspartic Acid Proteases | 2 | 2019 | 9 | 0.850 |
Why?
|
Lyme Disease | 4 | 2024 | 34 | 0.830 |
Why?
|
Protein Domains | 7 | 2021 | 314 | 0.820 |
Why?
|
Antibodies, Viral | 10 | 2023 | 1320 | 0.810 |
Why?
|
Political Systems | 1 | 2020 | 2 | 0.790 |
Why?
|
Humans | 146 | 2024 | 261506 | 0.780 |
Why?
|
Human Rights | 1 | 2020 | 21 | 0.780 |
Why?
|
Viral Envelope Proteins | 2 | 2020 | 207 | 0.760 |
Why?
|
Courage | 1 | 2020 | 3 | 0.760 |
Why?
|
Global Health | 7 | 2021 | 657 | 0.760 |
Why?
|
Vaccines, Subunit | 8 | 2021 | 124 | 0.750 |
Why?
|
Aspartic Acid Endopeptidases | 3 | 2018 | 44 | 0.740 |
Why?
|
Phospholipids | 2 | 2020 | 177 | 0.730 |
Why?
|
Developing Countries | 6 | 2020 | 315 | 0.730 |
Why?
|
Pepsin A | 1 | 2019 | 16 | 0.720 |
Why?
|
Fluorometry | 2 | 2017 | 34 | 0.710 |
Why?
|
Licensure | 1 | 2019 | 11 | 0.710 |
Why?
|
Mice | 52 | 2024 | 34495 | 0.700 |
Why?
|
Immunization | 7 | 2022 | 397 | 0.680 |
Why?
|
Emigrants and Immigrants | 3 | 2020 | 147 | 0.670 |
Why?
|
Anemia | 5 | 2021 | 689 | 0.660 |
Why?
|
Onchocerciasis | 4 | 2022 | 21 | 0.660 |
Why?
|
Parasites | 3 | 2024 | 20 | 0.650 |
Why?
|
Drug Design | 3 | 2020 | 375 | 0.650 |
Why?
|
Health Policy | 3 | 2020 | 291 | 0.650 |
Why?
|
Leishmania | 3 | 2023 | 24 | 0.640 |
Why?
|
Computational Biology | 2 | 2022 | 1271 | 0.640 |
Why?
|
Borrelia burgdorferi | 3 | 2024 | 15 | 0.640 |
Why?
|
Ancylostoma | 10 | 2015 | 97 | 0.640 |
Why?
|
Technology, Pharmaceutical | 4 | 2017 | 26 | 0.630 |
Why?
|
Onchocerciasis, Ocular | 1 | 2017 | 4 | 0.630 |
Why?
|
Mass Vaccination | 2 | 2016 | 21 | 0.610 |
Why?
|
Alum Compounds | 6 | 2021 | 42 | 0.610 |
Why?
|
Poverty | 7 | 2020 | 471 | 0.610 |
Why?
|
Onchocerca volvulus | 4 | 2019 | 14 | 0.600 |
Why?
|
Chemistry Techniques, Analytical | 1 | 2017 | 10 | 0.600 |
Why?
|
Ultraviolet Rays | 1 | 2019 | 575 | 0.600 |
Why?
|
Antibodies, Protozoan | 10 | 2019 | 87 | 0.590 |
Why?
|
Public Health | 3 | 2020 | 299 | 0.590 |
Why?
|
Immunogenicity, Vaccine | 5 | 2022 | 86 | 0.560 |
Why?
|
Trichuriasis | 4 | 2022 | 26 | 0.550 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2020 | 427 | 0.550 |
Why?
|
Calcium-Binding Proteins | 2 | 2017 | 545 | 0.550 |
Why?
|
Immunoglobulin G | 14 | 2023 | 1021 | 0.540 |
Why?
|
Helminths | 3 | 2024 | 37 | 0.540 |
Why?
|
Salivary Proteins and Peptides | 3 | 2020 | 18 | 0.530 |
Why?
|
Parasite Load | 7 | 2018 | 32 | 0.510 |
Why?
|
Latin America | 8 | 2020 | 115 | 0.500 |
Why?
|
Americas | 5 | 2020 | 52 | 0.490 |
Why?
|
Private Sector | 1 | 2014 | 32 | 0.480 |
Why?
|
Health Personnel | 1 | 2019 | 625 | 0.480 |
Why?
|
Disease Eradication | 2 | 2020 | 36 | 0.480 |
Why?
|
Immunoglobulin Fc Fragments | 2 | 2018 | 47 | 0.470 |
Why?
|
Cost-Benefit Analysis | 6 | 2021 | 945 | 0.460 |
Why?
|
Communication | 1 | 2020 | 876 | 0.460 |
Why?
|
Aluminum Hydroxide | 7 | 2023 | 40 | 0.460 |
Why?
|
Middle East Respiratory Syndrome Coronavirus | 3 | 2020 | 28 | 0.460 |
Why?
|
Immunoglobulin E | 2 | 2018 | 163 | 0.450 |
Why?
|
Histamine Release | 1 | 2012 | 15 | 0.440 |
Why?
|
Leishmaniasis, Cutaneous | 4 | 2020 | 46 | 0.440 |
Why?
|
Schistosoma mansoni | 5 | 2023 | 36 | 0.440 |
Why?
|
Basophils | 1 | 2012 | 38 | 0.440 |
Why?
|
Ixodes | 2 | 2022 | 16 | 0.430 |
Why?
|
Dengue | 1 | 2013 | 109 | 0.420 |
Why?
|
Occupational Medicine | 1 | 2011 | 4 | 0.400 |
Why?
|
Labor Unions | 1 | 2011 | 3 | 0.400 |
Why?
|
Accidents, Occupational | 1 | 2011 | 12 | 0.400 |
Why?
|
Emigration and Immigration | 2 | 2011 | 86 | 0.400 |
Why?
|
Work | 1 | 2011 | 24 | 0.390 |
Why?
|
Ancylostomiasis | 7 | 2015 | 62 | 0.380 |
Why?
|
Insect Proteins | 2 | 2020 | 91 | 0.370 |
Why?
|
Intestinal Diseases, Parasitic | 3 | 2020 | 36 | 0.360 |
Why?
|
Larva | 11 | 2024 | 274 | 0.350 |
Why?
|
Dogs | 10 | 2016 | 1155 | 0.340 |
Why?
|
Delivery of Health Care | 2 | 2019 | 860 | 0.340 |
Why?
|
Epitopes, T-Lymphocyte | 2 | 2021 | 219 | 0.330 |
Why?
|
Zika Virus Infection | 2 | 2022 | 166 | 0.330 |
Why?
|
Health Services Accessibility | 4 | 2020 | 761 | 0.330 |
Why?
|
Clinical Trials as Topic | 7 | 2020 | 3719 | 0.330 |
Why?
|
Antigenic Variation | 2 | 2021 | 38 | 0.320 |
Why?
|
Cloning, Molecular | 7 | 2021 | 1213 | 0.320 |
Why?
|
Internationality | 1 | 2009 | 208 | 0.320 |
Why?
|
Organizations, Nonprofit | 2 | 2015 | 22 | 0.310 |
Why?
|
Protein Stability | 4 | 2020 | 370 | 0.310 |
Why?
|
Research | 2 | 2020 | 415 | 0.310 |
Why?
|
Filariasis | 2 | 2018 | 24 | 0.310 |
Why?
|
Immunity, Cellular | 6 | 2022 | 419 | 0.300 |
Why?
|
Brugia malayi | 2 | 2018 | 41 | 0.300 |
Why?
|
Biotechnology | 3 | 2015 | 63 | 0.300 |
Why?
|
CD8-Positive T-Lymphocytes | 7 | 2022 | 1586 | 0.300 |
Why?
|
Lung Diseases | 2 | 2024 | 717 | 0.300 |
Why?
|
Rural Population | 2 | 2020 | 281 | 0.290 |
Why?
|
Psychodidae | 2 | 2017 | 12 | 0.290 |
Why?
|
Cultural Diversity | 2 | 2021 | 76 | 0.290 |
Why?
|
Honduras | 4 | 2020 | 21 | 0.290 |
Why?
|
Hydrogen-Ion Concentration | 3 | 2019 | 585 | 0.290 |
Why?
|
Superantigens | 2 | 2017 | 29 | 0.290 |
Why?
|
Leishmania donovani | 2 | 2016 | 13 | 0.290 |
Why?
|
Disease Outbreaks | 1 | 2009 | 415 | 0.290 |
Why?
|
Anthelmintics | 5 | 2016 | 69 | 0.290 |
Why?
|
N-Glycosyl Hydrolases | 2 | 2016 | 47 | 0.280 |
Why?
|
Swine Diseases | 2 | 2024 | 41 | 0.280 |
Why?
|
Budgets | 1 | 2006 | 25 | 0.280 |
Why?
|
Macaca mulatta | 4 | 2021 | 717 | 0.280 |
Why?
|
Female | 54 | 2023 | 141928 | 0.280 |
Why?
|
Lipid A | 4 | 2019 | 30 | 0.280 |
Why?
|
Protein Conformation | 4 | 2019 | 1258 | 0.280 |
Why?
|
Lung | 7 | 2024 | 3151 | 0.280 |
Why?
|
Cyclins | 3 | 2007 | 456 | 0.280 |
Why?
|
Temperature | 3 | 2017 | 506 | 0.270 |
Why?
|
Technology | 2 | 2024 | 96 | 0.270 |
Why?
|
Trichuris | 4 | 2022 | 19 | 0.270 |
Why?
|
Microbiota | 2 | 2023 | 547 | 0.270 |
Why?
|
Cytokines | 10 | 2021 | 2809 | 0.260 |
Why?
|
Amino Acid Sequence | 10 | 2021 | 4233 | 0.260 |
Why?
|
Toxocariasis | 2 | 2015 | 26 | 0.260 |
Why?
|
Vaccination Coverage | 2 | 2022 | 37 | 0.260 |
Why?
|
Computer Simulation | 4 | 2021 | 1529 | 0.250 |
Why?
|
Th2 Cells | 5 | 2021 | 257 | 0.250 |
Why?
|
Mitogens | 2 | 2001 | 75 | 0.250 |
Why?
|
Chitinases | 1 | 2024 | 4 | 0.250 |
Why?
|
Retinoblastoma Protein | 2 | 2005 | 335 | 0.240 |
Why?
|
Cost of Illness | 5 | 2016 | 498 | 0.240 |
Why?
|
Complement Factor H | 2 | 2022 | 33 | 0.240 |
Why?
|
Blood Donors | 2 | 2014 | 164 | 0.240 |
Why?
|
Human T-lymphotropic virus 1 | 4 | 2005 | 98 | 0.240 |
Why?
|
Antigens, Viral | 2 | 2018 | 471 | 0.230 |
Why?
|
Leishmania mexicana | 1 | 2023 | 4 | 0.230 |
Why?
|
Hypersensitivity | 2 | 2018 | 216 | 0.230 |
Why?
|
Disease Models, Animal | 15 | 2024 | 7222 | 0.230 |
Why?
|
Prevalence | 9 | 2024 | 3260 | 0.230 |
Why?
|
Technology Transfer | 2 | 2020 | 9 | 0.220 |
Why?
|
Borrelia burgdorferi Group | 1 | 2022 | 7 | 0.220 |
Why?
|
Endemic Diseases | 2 | 2012 | 67 | 0.220 |
Why?
|
Immunity | 3 | 2020 | 342 | 0.220 |
Why?
|
Drug Stability | 3 | 2017 | 105 | 0.210 |
Why?
|
Cytochalasin D | 1 | 2001 | 19 | 0.210 |
Why?
|
Microbiology | 1 | 2021 | 10 | 0.210 |
Why?
|
Glucosides | 2 | 2019 | 64 | 0.210 |
Why?
|
Growth Substances | 2 | 1999 | 300 | 0.210 |
Why?
|
Cyclin A | 1 | 2001 | 47 | 0.210 |
Why?
|
Intestinal Volvulus | 1 | 2022 | 33 | 0.210 |
Why?
|
Schistosomiasis haematobia | 1 | 2021 | 13 | 0.210 |
Why?
|
RNA, Protozoan | 1 | 2021 | 13 | 0.210 |
Why?
|
Immunoglobulin M | 3 | 2018 | 347 | 0.210 |
Why?
|
Host-Parasite Interactions | 2 | 2020 | 62 | 0.210 |
Why?
|
Vibrio cholerae | 1 | 2021 | 31 | 0.200 |
Why?
|
Cholera | 1 | 2021 | 27 | 0.200 |
Why?
|
Monocytes | 3 | 2020 | 788 | 0.200 |
Why?
|
Variant Surface Glycoproteins, Trypanosoma | 2 | 2018 | 6 | 0.200 |
Why?
|
Cyclin D1 | 4 | 2007 | 576 | 0.200 |
Why?
|
G1 Phase | 3 | 2007 | 285 | 0.200 |
Why?
|
Epitopes, B-Lymphocyte | 1 | 2021 | 32 | 0.200 |
Why?
|
Malaria, Falciparum | 1 | 2021 | 46 | 0.200 |
Why?
|
Borrelia | 1 | 2022 | 62 | 0.200 |
Why?
|
Bacterial Vaccines | 1 | 2021 | 103 | 0.200 |
Why?
|
Plasmodium falciparum | 1 | 2021 | 65 | 0.200 |
Why?
|
Clinical Laboratory Techniques | 2 | 2020 | 203 | 0.190 |
Why?
|
Vaccines, Inactivated | 1 | 2021 | 175 | 0.190 |
Why?
|
Lung Diseases, Parasitic | 1 | 2020 | 14 | 0.190 |
Why?
|
Toll-Like Receptor 4 | 2 | 2020 | 203 | 0.190 |
Why?
|
Cross Protection | 1 | 2020 | 10 | 0.190 |
Why?
|
Schistosoma haematobium | 2 | 2021 | 19 | 0.190 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2001 | 194 | 0.190 |
Why?
|
Blastocystis Infections | 1 | 2020 | 7 | 0.190 |
Why?
|
Blastocystis | 1 | 2020 | 5 | 0.190 |
Why?
|
Cysteine Endopeptidases | 3 | 2024 | 251 | 0.190 |
Why?
|
Health Communication | 1 | 2020 | 37 | 0.190 |
Why?
|
Cytoskeleton | 1 | 2001 | 267 | 0.180 |
Why?
|
Models, Economic | 2 | 2021 | 101 | 0.180 |
Why?
|
Th1 Cells | 5 | 2022 | 250 | 0.180 |
Why?
|
Ticks | 1 | 2020 | 32 | 0.180 |
Why?
|
Zika Virus | 1 | 2022 | 144 | 0.180 |
Why?
|
Monkey Diseases | 1 | 2020 | 50 | 0.180 |
Why?
|
Circular Dichroism | 3 | 2018 | 113 | 0.180 |
Why?
|
Politics | 1 | 2020 | 74 | 0.180 |
Why?
|
Neutralization Tests | 1 | 2020 | 299 | 0.180 |
Why?
|
Morals | 1 | 2020 | 70 | 0.180 |
Why?
|
Spectrophotometry, Ultraviolet | 1 | 2019 | 71 | 0.180 |
Why?
|
Heart | 6 | 2023 | 1223 | 0.180 |
Why?
|
Connective Tissue Growth Factor | 1 | 2019 | 45 | 0.180 |
Why?
|
T-Lymphocytes | 4 | 2021 | 3869 | 0.180 |
Why?
|
Health Care Costs | 2 | 2016 | 674 | 0.170 |
Why?
|
Soil | 4 | 2024 | 48 | 0.170 |
Why?
|
Protein Structure, Tertiary | 2 | 2021 | 1487 | 0.170 |
Why?
|
Sanitation | 2 | 2017 | 14 | 0.170 |
Why?
|
Respiratory Syncytial Viruses | 1 | 2020 | 171 | 0.170 |
Why?
|
Cysteine | 2 | 2017 | 214 | 0.170 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2019 | 157 | 0.170 |
Why?
|
CDC2-CDC28 Kinases | 1 | 1999 | 129 | 0.170 |
Why?
|
Eosinophils | 1 | 2020 | 162 | 0.170 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2020 | 280 | 0.170 |
Why?
|
Interleukin-17 | 1 | 2021 | 250 | 0.170 |
Why?
|
Protein Subunits | 1 | 2020 | 274 | 0.170 |
Why?
|
Antibodies, Catalytic | 1 | 2018 | 9 | 0.170 |
Why?
|
Lymphokines | 1 | 2019 | 272 | 0.170 |
Why?
|
Retinol-Binding Proteins | 1 | 2018 | 32 | 0.170 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 206 | 0.170 |
Why?
|
Th17 Cells | 1 | 2020 | 162 | 0.160 |
Why?
|
Candidemia | 1 | 2019 | 60 | 0.160 |
Why?
|
Actins | 1 | 2001 | 608 | 0.160 |
Why?
|
Vulnerable Populations | 1 | 2020 | 167 | 0.160 |
Why?
|
Artificial Intelligence | 1 | 2023 | 388 | 0.160 |
Why?
|
Nippostrongylus | 1 | 2018 | 2 | 0.160 |
Why?
|
Lyme Disease Vaccines | 3 | 2024 | 9 | 0.160 |
Why?
|
Antibody Formation | 5 | 2022 | 383 | 0.160 |
Why?
|
Respiratory Hypersensitivity | 1 | 2018 | 51 | 0.160 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2018 | 52 | 0.160 |
Why?
|
Biological Products | 1 | 2022 | 274 | 0.160 |
Why?
|
Protein Folding | 1 | 2019 | 281 | 0.160 |
Why?
|
Protective Agents | 1 | 2018 | 51 | 0.160 |
Why?
|
Strongylida Infections | 1 | 2018 | 15 | 0.160 |
Why?
|
Coinfection | 1 | 2020 | 189 | 0.160 |
Why?
|
Antibodies | 3 | 2022 | 838 | 0.160 |
Why?
|
Orthomyxoviridae Infections | 1 | 2018 | 72 | 0.160 |
Why?
|
Milk Proteins | 1 | 2018 | 116 | 0.160 |
Why?
|
Freezing | 1 | 2017 | 59 | 0.160 |
Why?
|
Plants, Genetically Modified | 2 | 2015 | 66 | 0.160 |
Why?
|
HLA-B Antigens | 1 | 2018 | 57 | 0.160 |
Why?
|
Cricetinae | 4 | 2012 | 706 | 0.160 |
Why?
|
Gabon | 3 | 2022 | 6 | 0.160 |
Why?
|
Mutant Proteins | 2 | 2016 | 234 | 0.160 |
Why?
|
Recombinant Fusion Proteins | 4 | 2023 | 1555 | 0.160 |
Why?
|
International Cooperation | 2 | 2022 | 323 | 0.160 |
Why?
|
Parasitemia | 4 | 2019 | 23 | 0.160 |
Why?
|
Premature Birth | 1 | 2022 | 407 | 0.150 |
Why?
|
HLA-A Antigens | 1 | 2018 | 102 | 0.150 |
Why?
|
Antiparasitic Agents | 1 | 2017 | 39 | 0.150 |
Why?
|
Epitopes | 4 | 2024 | 685 | 0.150 |
Why?
|
Gene Products, tax | 4 | 2005 | 74 | 0.150 |
Why?
|
Internet | 1 | 2022 | 706 | 0.150 |
Why?
|
Leukocytes, Mononuclear | 4 | 2018 | 709 | 0.150 |
Why?
|
Extracellular Matrix | 2 | 1999 | 554 | 0.150 |
Why?
|
Erythrocytes | 1 | 2018 | 339 | 0.140 |
Why?
|
Down-Regulation | 3 | 2007 | 2074 | 0.140 |
Why?
|
Fluorescence | 1 | 2017 | 195 | 0.140 |
Why?
|
Fatty Acid Transport Proteins | 1 | 2016 | 12 | 0.140 |
Why?
|
Housing | 2 | 2020 | 61 | 0.140 |
Why?
|
Chromatography, Gel | 2 | 2016 | 157 | 0.140 |
Why?
|
Leishmaniasis, Visceral | 1 | 2016 | 13 | 0.140 |
Why?
|
Tropical Climate | 2 | 2014 | 51 | 0.140 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2020 | 1217 | 0.140 |
Why?
|
Pregnancy Outcome | 1 | 2020 | 643 | 0.140 |
Why?
|
Brazil | 4 | 2023 | 165 | 0.140 |
Why?
|
Genetic Engineering | 1 | 2018 | 288 | 0.140 |
Why?
|
Myocardium | 2 | 2019 | 1313 | 0.140 |
Why?
|
Toxocara canis | 1 | 2015 | 5 | 0.140 |
Why?
|
Antiprotozoal Agents | 1 | 2016 | 40 | 0.140 |
Why?
|
Biophysical Phenomena | 2 | 2013 | 112 | 0.140 |
Why?
|
Interferon-gamma | 5 | 2019 | 1144 | 0.140 |
Why?
|
Drug Resistance | 1 | 2017 | 587 | 0.140 |
Why?
|
Immunotherapy | 3 | 2018 | 3341 | 0.140 |
Why?
|
Toll-Like Receptors | 1 | 2017 | 174 | 0.140 |
Why?
|
Seroepidemiologic Studies | 3 | 2024 | 129 | 0.130 |
Why?
|
Immunologic Memory | 1 | 2018 | 374 | 0.130 |
Why?
|
Drug Discovery | 2 | 2015 | 324 | 0.130 |
Why?
|
Primates | 1 | 2016 | 128 | 0.130 |
Why?
|
Promoter Regions, Genetic | 2 | 2007 | 3101 | 0.130 |
Why?
|
Immunodominant Epitopes | 1 | 2015 | 61 | 0.130 |
Why?
|
Staining and Labeling | 1 | 2017 | 429 | 0.130 |
Why?
|
Vaccines, DNA | 1 | 2016 | 105 | 0.130 |
Why?
|
Metalloendopeptidases | 2 | 2006 | 170 | 0.130 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2021 | 1498 | 0.130 |
Why?
|
Acute Disease | 2 | 2018 | 2422 | 0.130 |
Why?
|
United States | 8 | 2021 | 15433 | 0.130 |
Why?
|
T-Lymphocyte Subsets | 1 | 2018 | 582 | 0.130 |
Why?
|
STAT3 Transcription Factor | 1 | 2021 | 1121 | 0.130 |
Why?
|
Software | 1 | 2022 | 1321 | 0.130 |
Why?
|
Central America | 1 | 2014 | 29 | 0.120 |
Why?
|
Membrane Proteins | 2 | 2024 | 2819 | 0.120 |
Why?
|
Fluorescent Dyes | 1 | 2017 | 459 | 0.120 |
Why?
|
Universities | 1 | 2015 | 160 | 0.120 |
Why?
|
Fund Raising | 1 | 2014 | 4 | 0.120 |
Why?
|
Cell- and Tissue-Based Therapy | 1 | 2017 | 406 | 0.120 |
Why?
|
Caribbean Region | 1 | 2014 | 23 | 0.120 |
Why?
|
Poverty Areas | 1 | 2014 | 37 | 0.120 |
Why?
|
Bacterial Proteins | 1 | 2020 | 1029 | 0.120 |
Why?
|
Viral Load | 3 | 2021 | 493 | 0.120 |
Why?
|
Transforming Growth Factor beta | 1 | 2019 | 1130 | 0.120 |
Why?
|
Escherichia coli | 4 | 2024 | 1203 | 0.120 |
Why?
|
Mice, Inbred C57BL | 6 | 2023 | 6942 | 0.120 |
Why?
|
Excipients | 1 | 2013 | 17 | 0.120 |
Why?
|
Antigens, Bacterial | 1 | 2016 | 354 | 0.120 |
Why?
|
Skin | 2 | 2012 | 1259 | 0.120 |
Why?
|
Capacity Building | 1 | 2013 | 30 | 0.120 |
Why?
|
Education, Graduate | 1 | 2013 | 24 | 0.120 |
Why?
|
Immunoglobulins | 2 | 2012 | 266 | 0.120 |
Why?
|
Drug Compounding | 1 | 2013 | 70 | 0.120 |
Why?
|
Retroviridae Proteins, Oncogenic | 1 | 1993 | 36 | 0.110 |
Why?
|
Cell Line | 7 | 2021 | 5114 | 0.110 |
Why?
|
Male | 26 | 2021 | 123000 | 0.110 |
Why?
|
Research Support as Topic | 1 | 2014 | 122 | 0.110 |
Why?
|
Cardiomyopathies | 1 | 2019 | 610 | 0.110 |
Why?
|
Leukemia, Monocytic, Acute | 1 | 1993 | 31 | 0.110 |
Why?
|
Cuba | 2 | 2022 | 10 | 0.110 |
Why?
|
Up-Regulation | 1 | 1999 | 2450 | 0.110 |
Why?
|
Intestinal Diseases | 1 | 2014 | 121 | 0.110 |
Why?
|
Registries | 1 | 2020 | 2170 | 0.110 |
Why?
|
Influenza Vaccines | 1 | 2018 | 635 | 0.110 |
Why?
|
Immunotherapy, Active | 1 | 2012 | 46 | 0.110 |
Why?
|
Mexico | 3 | 2020 | 259 | 0.110 |
Why?
|
Necatoriasis | 2 | 2010 | 31 | 0.110 |
Why?
|
Plasmodium vivax | 1 | 2012 | 9 | 0.110 |
Why?
|
Chronic Disease | 5 | 2021 | 1819 | 0.110 |
Why?
|
CD13 Antigens | 1 | 2012 | 36 | 0.110 |
Why?
|
Malaria Vaccines | 1 | 2012 | 20 | 0.100 |
Why?
|
Life Cycle Stages | 3 | 2020 | 27 | 0.100 |
Why?
|
Ascaris | 2 | 2024 | 9 | 0.100 |
Why?
|
Program Development | 1 | 2013 | 261 | 0.100 |
Why?
|
Research Personnel | 1 | 2013 | 156 | 0.100 |
Why?
|
Feces | 4 | 2024 | 770 | 0.100 |
Why?
|
Quality-Adjusted Life Years | 3 | 2020 | 226 | 0.100 |
Why?
|
Disabled Persons | 1 | 2013 | 121 | 0.100 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 568 | 0.100 |
Why?
|
Socioeconomic Factors | 4 | 2020 | 1225 | 0.100 |
Why?
|
Administration, Intranasal | 2 | 2022 | 190 | 0.100 |
Why?
|
Molecular Sequence Data | 9 | 2011 | 6089 | 0.100 |
Why?
|
Insect Vectors | 1 | 2012 | 110 | 0.100 |
Why?
|
Young Adult | 9 | 2021 | 21445 | 0.100 |
Why?
|
Reproducibility of Results | 1 | 2021 | 6009 | 0.100 |
Why?
|
B-Lymphocytes | 4 | 2021 | 1294 | 0.100 |
Why?
|
Patient Rights | 1 | 2011 | 54 | 0.100 |
Why?
|
Italy | 1 | 2011 | 236 | 0.100 |
Why?
|
Mice, Inbred AKR | 2 | 2022 | 51 | 0.100 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2012 | 548 | 0.090 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2004 | 528 | 0.090 |
Why?
|
Factor Xa Inhibitors | 1 | 2011 | 70 | 0.090 |
Why?
|
Gene Expression Regulation | 5 | 2020 | 4053 | 0.090 |
Why?
|
Nuclear Proteins | 1 | 2001 | 3343 | 0.090 |
Why?
|
Hepatitis B Vaccines | 2 | 2022 | 51 | 0.090 |
Why?
|
Chlamydia trachomatis | 1 | 2009 | 30 | 0.090 |
Why?
|
Severity of Illness Index | 1 | 2020 | 4320 | 0.090 |
Why?
|
Heme | 1 | 2010 | 78 | 0.090 |
Why?
|
Pregnancy | 5 | 2022 | 7573 | 0.090 |
Why?
|
Esophagus | 2 | 2011 | 553 | 0.090 |
Why?
|
Oncogenes | 1 | 1993 | 673 | 0.090 |
Why?
|
Aging | 1 | 2018 | 1582 | 0.090 |
Why?
|
Porins | 1 | 2009 | 55 | 0.090 |
Why?
|
Sequence Alignment | 4 | 2017 | 844 | 0.090 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 2 | 2001 | 280 | 0.090 |
Why?
|
Fermentation | 2 | 2020 | 60 | 0.090 |
Why?
|
Genetic Vectors | 3 | 2020 | 1694 | 0.080 |
Why?
|
Insurance, Health | 1 | 2011 | 250 | 0.080 |
Why?
|
Binding Sites | 3 | 2022 | 2171 | 0.080 |
Why?
|
Insurance Coverage | 1 | 2011 | 256 | 0.080 |
Why?
|
Adult | 15 | 2022 | 77950 | 0.080 |
Why?
|
Immunohistochemistry | 2 | 2018 | 7548 | 0.080 |
Why?
|
World Health Organization | 3 | 2016 | 316 | 0.080 |
Why?
|
Interleukin-5 | 2 | 2018 | 73 | 0.080 |
Why?
|
Risk Factors | 5 | 2020 | 17523 | 0.080 |
Why?
|
Metabolome | 2 | 2021 | 344 | 0.080 |
Why?
|
Healthy Volunteers | 2 | 2019 | 187 | 0.080 |
Why?
|
Molecular Weight | 2 | 2020 | 629 | 0.080 |
Why?
|
Viral Regulatory and Accessory Proteins | 2 | 2004 | 64 | 0.080 |
Why?
|
Membrane Glycoproteins | 1 | 2012 | 1073 | 0.080 |
Why?
|
Gerbillinae | 2 | 2018 | 52 | 0.080 |
Why?
|
Health Status | 1 | 2011 | 590 | 0.080 |
Why?
|
Protein Processing, Post-Translational | 2 | 2018 | 803 | 0.080 |
Why?
|
3T3 Cells | 3 | 2004 | 355 | 0.080 |
Why?
|
Interleukin-4 | 2 | 2018 | 284 | 0.080 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2020 | 1489 | 0.080 |
Why?
|
Swine | 2 | 2024 | 1541 | 0.070 |
Why?
|
Dog Diseases | 2 | 2005 | 73 | 0.070 |
Why?
|
Gene Expression Regulation, Viral | 2 | 2004 | 187 | 0.070 |
Why?
|
Adolescent | 10 | 2020 | 31252 | 0.070 |
Why?
|
Viral Proteins | 2 | 2014 | 435 | 0.070 |
Why?
|
Cell Cycle | 6 | 2007 | 2084 | 0.070 |
Why?
|
Flow Cytometry | 3 | 2023 | 3033 | 0.070 |
Why?
|
Markov Chains | 2 | 2020 | 175 | 0.070 |
Why?
|
Connective Tissue | 1 | 2006 | 43 | 0.070 |
Why?
|
Fibrosis | 2 | 2019 | 793 | 0.070 |
Why?
|
Mass Screening | 1 | 2014 | 1509 | 0.070 |
Why?
|
Cell Adhesion | 3 | 1999 | 1008 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2004 | 2359 | 0.070 |
Why?
|
Transcriptional Activation | 3 | 2014 | 1070 | 0.070 |
Why?
|
Protein Binding | 3 | 2021 | 3438 | 0.070 |
Why?
|
Disease Progression | 3 | 2023 | 6682 | 0.070 |
Why?
|
Survival Analysis | 4 | 2018 | 9180 | 0.070 |
Why?
|
Antinematodal Agents | 1 | 2005 | 19 | 0.060 |
Why?
|
Texas | 4 | 2021 | 6311 | 0.060 |
Why?
|
Anticoagulants | 1 | 2011 | 787 | 0.060 |
Why?
|
Lymphocyte Activation | 2 | 2007 | 1688 | 0.060 |
Why?
|
Fibroblasts | 3 | 2019 | 1682 | 0.060 |
Why?
|
Dose-Response Relationship, Immunologic | 2 | 2020 | 182 | 0.060 |
Why?
|
Biomarkers | 3 | 2021 | 5047 | 0.060 |
Why?
|
Peptides | 1 | 2011 | 1479 | 0.060 |
Why?
|
Immunity, Innate | 2 | 2020 | 677 | 0.060 |
Why?
|
Double-Blind Method | 2 | 2020 | 2588 | 0.060 |
Why?
|
Protein Structure, Secondary | 2 | 2018 | 336 | 0.060 |
Why?
|
Middle Aged | 12 | 2021 | 86204 | 0.060 |
Why?
|
Virus Replication | 2 | 2004 | 709 | 0.060 |
Why?
|
Chemistry, Pharmaceutical | 1 | 2014 | 84 | 0.060 |
Why?
|
Hepatomegaly | 1 | 2023 | 69 | 0.060 |
Why?
|
BRCA1 Protein | 1 | 2007 | 493 | 0.060 |
Why?
|
Vaccines, Combined | 1 | 2023 | 39 | 0.060 |
Why?
|
PPAR alpha | 1 | 2023 | 62 | 0.060 |
Why?
|
Phylogeny | 2 | 2020 | 826 | 0.060 |
Why?
|
Public-Private Sector Partnerships | 2 | 2013 | 26 | 0.060 |
Why?
|
North America | 2 | 2014 | 314 | 0.060 |
Why?
|
Bacterial Outer Membrane Proteins | 1 | 2024 | 122 | 0.060 |
Why?
|
Malaria | 2 | 2015 | 92 | 0.060 |
Why?
|
Culture Media | 1 | 2014 | 319 | 0.060 |
Why?
|
Child | 9 | 2024 | 29154 | 0.060 |
Why?
|
Infection Control | 1 | 2005 | 270 | 0.060 |
Why?
|
RNA, Messenger | 3 | 2024 | 6150 | 0.060 |
Why?
|
Nerve Tissue Proteins | 1 | 2010 | 1491 | 0.060 |
Why?
|
Environment | 1 | 2024 | 190 | 0.060 |
Why?
|
Onchocerca | 1 | 2022 | 5 | 0.050 |
Why?
|
Intestines | 3 | 2017 | 686 | 0.050 |
Why?
|
Chromatography, Liquid | 1 | 2014 | 342 | 0.050 |
Why?
|
Parasite Egg Count | 3 | 2007 | 33 | 0.050 |
Why?
|
Cooperative Behavior | 2 | 2015 | 313 | 0.050 |
Why?
|
Ivermectin | 1 | 2022 | 20 | 0.050 |
Why?
|
Tissue Distribution | 1 | 2024 | 875 | 0.050 |
Why?
|
Retinoblastoma-Like Protein p107 | 1 | 2001 | 7 | 0.050 |
Why?
|
Mammals | 1 | 2024 | 361 | 0.050 |
Why?
|
Antigens | 1 | 2023 | 292 | 0.050 |
Why?
|
Infant, Low Birth Weight | 1 | 2022 | 181 | 0.050 |
Why?
|
Risk Assessment | 1 | 2014 | 6869 | 0.050 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2005 | 589 | 0.050 |
Why?
|
Blindness | 1 | 2022 | 77 | 0.050 |
Why?
|
Hybridomas | 1 | 2021 | 75 | 0.050 |
Why?
|
Masks | 1 | 2022 | 57 | 0.050 |
Why?
|
Immunity, Mucosal | 1 | 2022 | 108 | 0.050 |
Why?
|
Infant | 4 | 2022 | 13310 | 0.050 |
Why?
|
China | 2 | 2019 | 606 | 0.050 |
Why?
|
Echocardiography | 2 | 2019 | 1182 | 0.050 |
Why?
|
DNA, Complementary | 2 | 2015 | 869 | 0.050 |
Why?
|
Treatment Outcome | 6 | 2020 | 32848 | 0.050 |
Why?
|
Morbidity | 1 | 2022 | 397 | 0.050 |
Why?
|
Australia | 1 | 2021 | 225 | 0.050 |
Why?
|
Immunoglobulin A | 1 | 2022 | 237 | 0.050 |
Why?
|
Synteny | 1 | 2021 | 87 | 0.050 |
Why?
|
Tropism | 1 | 2020 | 19 | 0.050 |
Why?
|
Mucous Membrane | 1 | 2022 | 271 | 0.050 |
Why?
|
Stomach | 1 | 2024 | 387 | 0.050 |
Why?
|
Employment | 1 | 2021 | 129 | 0.050 |
Why?
|
Viral Nonstructural Proteins | 1 | 2022 | 163 | 0.050 |
Why?
|
Protease Inhibitors | 1 | 2022 | 210 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2011 | 2403 | 0.050 |
Why?
|
Unemployment | 1 | 2020 | 31 | 0.050 |
Why?
|
Administration, Inhalation | 1 | 2021 | 285 | 0.050 |
Why?
|
Cattle | 1 | 2022 | 783 | 0.050 |
Why?
|
Medically Underserved Area | 1 | 2020 | 101 | 0.050 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2021 | 1033 | 0.050 |
Why?
|
Transcription, Genetic | 3 | 2004 | 3154 | 0.050 |
Why?
|
Receptors, Fibronectin | 1 | 1999 | 25 | 0.050 |
Why?
|
Phosphorylation | 3 | 2007 | 4804 | 0.050 |
Why?
|
Aged | 9 | 2022 | 70117 | 0.040 |
Why?
|
Aluminum Compounds | 2 | 2012 | 17 | 0.040 |
Why?
|
Endothelin-1 | 1 | 2019 | 60 | 0.040 |
Why?
|
Mice, Inbred C3H | 1 | 2020 | 385 | 0.040 |
Why?
|
Food Supply | 1 | 2020 | 97 | 0.040 |
Why?
|
Adaptive Immunity | 1 | 2020 | 149 | 0.040 |
Why?
|
Multigene Family | 1 | 2021 | 425 | 0.040 |
Why?
|
HIV-1 | 1 | 2004 | 653 | 0.040 |
Why?
|
Nifurtimox | 1 | 2019 | 3 | 0.040 |
Why?
|
Complement System Proteins | 1 | 2020 | 139 | 0.040 |
Why?
|
Child, Preschool | 5 | 2017 | 16273 | 0.040 |
Why?
|
Editorial Policies | 1 | 2020 | 87 | 0.040 |
Why?
|
Cell Differentiation | 3 | 2023 | 4078 | 0.040 |
Why?
|
Enzyme Activation | 2 | 1999 | 1764 | 0.040 |
Why?
|
Organ Specificity | 1 | 2020 | 699 | 0.040 |
Why?
|
Immunomodulation | 1 | 2020 | 242 | 0.040 |
Why?
|
Needs Assessment | 1 | 2020 | 233 | 0.040 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2019 | 136 | 0.040 |
Why?
|
Mice, Inbred ICR | 1 | 2019 | 239 | 0.040 |
Why?
|
RNA | 1 | 2024 | 1013 | 0.040 |
Why?
|
Pregnant Women | 1 | 2020 | 162 | 0.040 |
Why?
|
Neoplasm Proteins | 1 | 2010 | 3230 | 0.040 |
Why?
|
Ovalbumin | 1 | 2018 | 254 | 0.040 |
Why?
|
Receptors, CXCR3 | 1 | 2018 | 36 | 0.040 |
Why?
|
Mice, Knockout | 2 | 2018 | 5710 | 0.040 |
Why?
|
Receptors, CCR2 | 1 | 2018 | 41 | 0.040 |
Why?
|
Interleukin-13 | 1 | 2018 | 135 | 0.040 |
Why?
|
Vitamin A | 1 | 2018 | 94 | 0.040 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2020 | 242 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 2 | 1 | 1999 | 249 | 0.040 |
Why?
|
Health Services | 1 | 2018 | 105 | 0.040 |
Why?
|
Chemokines | 1 | 2019 | 314 | 0.040 |
Why?
|
Alabama | 1 | 2017 | 39 | 0.040 |
Why?
|
Cyclin-Dependent Kinases | 1 | 1999 | 311 | 0.040 |
Why?
|
Entamoeba histolytica | 1 | 2017 | 18 | 0.040 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2018 | 254 | 0.040 |
Why?
|
Cricetulus | 1 | 2018 | 205 | 0.040 |
Why?
|
Disease Susceptibility | 1 | 2020 | 538 | 0.040 |
Why?
|
Time Factors | 3 | 2017 | 12926 | 0.040 |
Why?
|
Strongyloides stercoralis | 1 | 2017 | 22 | 0.040 |
Why?
|
Proteome | 1 | 2021 | 561 | 0.040 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2018 | 182 | 0.040 |
Why?
|
CHO Cells | 1 | 2018 | 311 | 0.040 |
Why?
|
Industrial Microbiology | 1 | 2017 | 7 | 0.040 |
Why?
|
Cryptosporidium | 1 | 2017 | 47 | 0.040 |
Why?
|
Sequence Analysis | 1 | 2017 | 73 | 0.040 |
Why?
|
Cholera Toxin | 1 | 2017 | 63 | 0.040 |
Why?
|
MAP Kinase Signaling System | 1 | 2001 | 848 | 0.040 |
Why?
|
CTLA-4 Antigen | 1 | 2021 | 657 | 0.040 |
Why?
|
Vaccine Potency | 1 | 2017 | 8 | 0.040 |
Why?
|
Cyclin E | 1 | 1999 | 267 | 0.040 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2018 | 212 | 0.040 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2018 | 155 | 0.040 |
Why?
|
Hydrolysis | 1 | 2017 | 227 | 0.040 |
Why?
|
Drug Storage | 1 | 2017 | 29 | 0.040 |
Why?
|
Cell Proliferation | 4 | 2018 | 7226 | 0.040 |
Why?
|
Injections, Intramuscular | 1 | 2017 | 255 | 0.040 |
Why?
|
Infant, Newborn | 2 | 2022 | 8223 | 0.040 |
Why?
|
Dynamic Light Scattering | 1 | 2016 | 9 | 0.040 |
Why?
|
Cyclin D2 | 2 | 2007 | 40 | 0.030 |
Why?
|
Transduction, Genetic | 1 | 2017 | 475 | 0.030 |
Why?
|
Drug Carriers | 1 | 2017 | 327 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2018 | 478 | 0.030 |
Why?
|
Drug Evaluation | 1 | 2016 | 425 | 0.030 |
Why?
|
Serine | 1 | 2017 | 388 | 0.030 |
Why?
|
Asia, Southeastern | 1 | 2015 | 23 | 0.030 |
Why?
|
Lectins | 1 | 2015 | 151 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2020 | 1038 | 0.030 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2016 | 261 | 0.030 |
Why?
|
Drug Industry | 1 | 2015 | 88 | 0.030 |
Why?
|
Antibody Specificity | 1 | 2015 | 334 | 0.030 |
Why?
|
Proto-Oncogenes | 1 | 1995 | 202 | 0.030 |
Why?
|
Mutagenesis | 1 | 2016 | 483 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 2 | 1995 | 2488 | 0.030 |
Why?
|
Protein Multimerization | 1 | 2016 | 240 | 0.030 |
Why?
|
Gene Frequency | 1 | 2018 | 1163 | 0.030 |
Why?
|
Protein Isoforms | 1 | 2017 | 842 | 0.030 |
Why?
|
Healthcare Disparities | 1 | 2020 | 598 | 0.030 |
Why?
|
Antiviral Agents | 1 | 2022 | 1230 | 0.030 |
Why?
|
Topography, Medical | 1 | 2014 | 6 | 0.030 |
Why?
|
Proteins | 1 | 2023 | 1963 | 0.030 |
Why?
|
Parasitology | 1 | 2014 | 9 | 0.030 |
Why?
|
Muscles | 1 | 1995 | 416 | 0.030 |
Why?
|
Mice, SCID | 1 | 2018 | 1869 | 0.030 |
Why?
|
Ascaris lumbricoides | 1 | 2014 | 19 | 0.030 |
Why?
|
Goals | 1 | 2015 | 185 | 0.030 |
Why?
|
Myocytes, Cardiac | 1 | 2019 | 764 | 0.030 |
Why?
|
Aged, 80 and over | 4 | 2017 | 29902 | 0.030 |
Why?
|
Incidence | 2 | 2014 | 5673 | 0.030 |
Why?
|
Neutrophils | 1 | 2018 | 835 | 0.030 |
Why?
|
Organizational Objectives | 1 | 2013 | 61 | 0.030 |
Why?
|
Public Sector | 1 | 2013 | 11 | 0.030 |
Why?
|
Glycosylation | 1 | 2013 | 213 | 0.030 |
Why?
|
Oncogene Proteins v-myb | 1 | 1993 | 8 | 0.030 |
Why?
|
Quality Control | 1 | 2015 | 457 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2018 | 1681 | 0.030 |
Why?
|
South America | 1 | 2013 | 52 | 0.030 |
Why?
|
Absenteeism | 1 | 2013 | 24 | 0.030 |
Why?
|
Spleen | 1 | 2015 | 676 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myb | 1 | 1993 | 47 | 0.030 |
Why?
|
Chick Embryo | 1 | 1993 | 242 | 0.030 |
Why?
|
Viscera | 1 | 2013 | 81 | 0.030 |
Why?
|
Influenza, Human | 1 | 2020 | 925 | 0.030 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2015 | 247 | 0.030 |
Why?
|
Hypertrophy | 1 | 2013 | 162 | 0.030 |
Why?
|
Cell Line, Transformed | 1 | 1993 | 394 | 0.030 |
Why?
|
Efficiency | 1 | 2013 | 99 | 0.030 |
Why?
|
Academies and Institutes | 1 | 2013 | 95 | 0.030 |
Why?
|
Plasmodium berghei | 1 | 2012 | 13 | 0.030 |
Why?
|
Anopheles | 1 | 2012 | 28 | 0.030 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 598 | 0.030 |
Why?
|
Phosphates | 1 | 2012 | 187 | 0.030 |
Why?
|
Macrophages | 1 | 2018 | 1304 | 0.030 |
Why?
|
Adenoviridae | 1 | 2017 | 1459 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2018 | 3203 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 4971 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2012 | 306 | 0.030 |
Why?
|
Nanoparticles | 1 | 2016 | 554 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 4938 | 0.020 |
Why?
|
Europe | 1 | 2013 | 649 | 0.020 |
Why?
|
Dendritic Cells | 1 | 2017 | 1085 | 0.020 |
Why?
|
Models, Molecular | 1 | 2016 | 1732 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2018 | 1270 | 0.020 |
Why?
|
Crystallization | 1 | 2010 | 132 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 2 | 2005 | 2063 | 0.020 |
Why?
|
Solubility | 1 | 2010 | 242 | 0.020 |
Why?
|
DNA, Helminth | 1 | 2010 | 22 | 0.020 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2013 | 604 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2018 | 2483 | 0.020 |
Why?
|
Base Sequence | 2 | 1995 | 4917 | 0.020 |
Why?
|
Apoptosis | 4 | 2005 | 7591 | 0.020 |
Why?
|
HIV Infections | 2 | 2015 | 2134 | 0.020 |
Why?
|
Blood Coagulation | 1 | 2011 | 185 | 0.020 |
Why?
|
Genotype | 1 | 2018 | 4109 | 0.020 |
Why?
|
Blotting, Western | 1 | 2015 | 3536 | 0.020 |
Why?
|
Chlamydia Infections | 1 | 2009 | 51 | 0.020 |
Why?
|
Lipid Peroxidation | 1 | 2010 | 157 | 0.020 |
Why?
|
Genetic Variation | 1 | 2018 | 2086 | 0.020 |
Why?
|
Open Reading Frames | 1 | 2010 | 250 | 0.020 |
Why?
|
Thermodynamics | 1 | 2009 | 196 | 0.020 |
Why?
|
Spectrometry, Fluorescence | 1 | 2009 | 209 | 0.020 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2013 | 419 | 0.020 |
Why?
|
West Indies | 1 | 2008 | 8 | 0.020 |
Why?
|
Crystallography, X-Ray | 1 | 2010 | 627 | 0.020 |
Why?
|
Chromatin | 2 | 2004 | 942 | 0.020 |
Why?
|
Electrocardiography | 1 | 2014 | 1145 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2021 | 4367 | 0.020 |
Why?
|
Pneumonia, Bacterial | 1 | 2009 | 130 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2010 | 997 | 0.020 |
Why?
|
Thinness | 1 | 2008 | 82 | 0.020 |
Why?
|
Cyclin D3 | 1 | 2007 | 23 | 0.020 |
Why?
|
Pilot Projects | 1 | 2014 | 2803 | 0.020 |
Why?
|
Glutathione | 1 | 2010 | 368 | 0.020 |
Why?
|
Income | 1 | 2008 | 222 | 0.020 |
Why?
|
Resting Phase, Cell Cycle | 1 | 2007 | 35 | 0.020 |
Why?
|
Cells, Cultured | 2 | 2007 | 5637 | 0.020 |
Why?
|
Multiprotein Complexes | 1 | 2009 | 395 | 0.020 |
Why?
|
In Vitro Techniques | 1 | 2009 | 1618 | 0.020 |
Why?
|
Cohort Studies | 1 | 2019 | 9244 | 0.020 |
Why?
|
Alleles | 1 | 1993 | 2437 | 0.020 |
Why?
|
CD3 Complex | 1 | 2007 | 314 | 0.020 |
Why?
|
Rats | 2 | 2005 | 6086 | 0.020 |
Why?
|
Quillaja Saponins | 1 | 2005 | 2 | 0.020 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2008 | 362 | 0.020 |
Why?
|
Saponins | 1 | 2005 | 34 | 0.020 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2007 | 198 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2015 | 6100 | 0.020 |
Why?
|
Mesocricetus | 1 | 2005 | 114 | 0.020 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2007 | 518 | 0.020 |
Why?
|
Signal Transduction | 2 | 2004 | 11965 | 0.020 |
Why?
|
Surveys and Questionnaires | 1 | 2017 | 5687 | 0.020 |
Why?
|
Leupeptins | 1 | 2005 | 68 | 0.020 |
Why?
|
Human Immunodeficiency Virus Proteins | 1 | 2004 | 3 | 0.020 |
Why?
|
vif Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 3 | 0.020 |
Why?
|
Gene Products, rev | 1 | 2004 | 8 | 0.020 |
Why?
|
Gene Products, vif | 1 | 2004 | 3 | 0.020 |
Why?
|
Necator | 1 | 2004 | 2 | 0.020 |
Why?
|
Larva Migrans | 1 | 2004 | 6 | 0.020 |
Why?
|
nef Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 18 | 0.020 |
Why?
|
Gene Products, nef | 1 | 2004 | 15 | 0.020 |
Why?
|
rev Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 14 | 0.020 |
Why?
|
Retrospective Studies | 2 | 2020 | 37905 | 0.020 |
Why?
|
vpr Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 20 | 0.020 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 45 | 0.020 |
Why?
|
Gene Products, vpr | 1 | 2004 | 24 | 0.020 |
Why?
|
Gene Products, tat | 1 | 2004 | 54 | 0.020 |
Why?
|
Weight Loss | 1 | 2009 | 627 | 0.020 |
Why?
|
Sex Ratio | 1 | 2004 | 15 | 0.020 |
Why?
|
Leukemia, T-Cell | 1 | 2004 | 87 | 0.020 |
Why?
|
Cell Transformation, Viral | 1 | 2004 | 138 | 0.020 |
Why?
|
Amino Acid Motifs | 1 | 2005 | 392 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2005 | 591 | 0.010 |
Why?
|
HTLV-I Infections | 1 | 2003 | 16 | 0.010 |
Why?
|
Oncogene Proteins, Viral | 1 | 2004 | 133 | 0.010 |
Why?
|
Lymphocyte Count | 1 | 2005 | 486 | 0.010 |
Why?
|
Peptide Mapping | 1 | 2003 | 114 | 0.010 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2004 | 323 | 0.010 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 2003 | 65 | 0.010 |
Why?
|
Proteasome Inhibitors | 1 | 2005 | 231 | 0.010 |
Why?
|
Cell Division | 2 | 1999 | 2489 | 0.010 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2003 | 208 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 7702 | 0.010 |
Why?
|
Travel | 1 | 2004 | 190 | 0.010 |
Why?
|
Schools | 1 | 2004 | 233 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2007 | 15694 | 0.010 |
Why?
|
Gastrointestinal Tract | 1 | 2005 | 324 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 1995 | 4821 | 0.010 |
Why?
|
Mitosis | 1 | 2004 | 615 | 0.010 |
Why?
|
Regression Analysis | 1 | 2005 | 1546 | 0.010 |
Why?
|
Microscopy, Confocal | 1 | 2004 | 663 | 0.010 |
Why?
|
Benzimidazoles | 1 | 2004 | 428 | 0.010 |
Why?
|
Survival Rate | 1 | 2014 | 12221 | 0.010 |
Why?
|
Hemorrhage | 1 | 2005 | 712 | 0.010 |
Why?
|
Lymphocytes | 1 | 2005 | 1234 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2014 | 14889 | 0.010 |
Why?
|
Fibronectins | 1 | 1999 | 197 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2004 | 1620 | 0.010 |
Why?
|
Heart Failure | 1 | 2013 | 2516 | 0.010 |
Why?
|
DNA | 1 | 2007 | 2693 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2003 | 1271 | 0.010 |
Why?
|
Mutation | 1 | 2017 | 15179 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 1999 | 1062 | 0.010 |
Why?
|
DNA Repair | 1 | 2004 | 1872 | 0.010 |
Why?
|
Research Design | 1 | 2003 | 1544 | 0.010 |
Why?
|
Quail | 1 | 1995 | 7 | 0.010 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 1999 | 661 | 0.010 |
Why?
|
Transfection | 1 | 1999 | 2944 | 0.010 |
Why?
|
Alternative Splicing | 1 | 1995 | 584 | 0.010 |
Why?
|
Exons | 1 | 1995 | 1328 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2007 | 14551 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2007 | 8873 | 0.010 |
Why?
|